We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

Canagliflozin

From Proteopedia

(Redirected from Sulisent)
Jump to: navigation, search

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. ↑ "Canagliflozin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.
  2. ↑ "Integrity - Clarivate"
  3. ↑ Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. PMID:32064793 doi:10.1002/psp4.12498
  4. ↑ Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? Drugs. 2021 Aug;81(12):1365-1371. PMID:34232488 doi:10.1007/s40265-021-01559-1
  5. ↑ Klement A (20 January 2014). "Tubuläre Senkung des Blutzuckers bei Diabetes mellitus: Invokana". Österreichische Apothekerzeitung (in German) (2/2014): 20f.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Retrieved from "http://proteopedia.org/wiki/index.php/Canagliflozin"
Personal tools